Trade Longeveron Inc. - LGVN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.95 |
| Open | 1.97 |
| 1-Year Change | -16.88% |
| Day's Range | 1.97 - 2.1 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 9, 2024 | 2.06 | 0.16 | 8.42% | 1.90 | 2.11 | 1.90 |
| Sep 6, 2024 | 1.95 | -0.18 | -8.45% | 2.13 | 2.13 | 1.93 |
| Sep 5, 2024 | 2.14 | 0.04 | 1.90% | 2.10 | 2.18 | 2.04 |
| Sep 4, 2024 | 2.15 | 0.16 | 8.04% | 1.99 | 2.17 | 1.90 |
| Sep 3, 2024 | 2.03 | 0.00 | 0.00% | 2.03 | 2.14 | 1.96 |
| Aug 30, 2024 | 2.04 | -0.02 | -0.97% | 2.06 | 2.06 | 1.96 |
| Aug 29, 2024 | 2.08 | 0.05 | 2.46% | 2.03 | 2.09 | 1.96 |
| Aug 28, 2024 | 2.09 | -0.16 | -7.11% | 2.25 | 2.29 | 2.02 |
| Aug 27, 2024 | 2.26 | -0.03 | -1.31% | 2.29 | 2.41 | 2.25 |
| Aug 26, 2024 | 2.38 | -0.16 | -6.30% | 2.54 | 2.58 | 2.30 |
| Aug 23, 2024 | 2.55 | -0.05 | -1.92% | 2.60 | 2.64 | 2.52 |
| Aug 22, 2024 | 2.61 | 0.10 | 3.98% | 2.51 | 2.84 | 2.50 |
| Aug 21, 2024 | 2.54 | 0.33 | 14.93% | 2.21 | 2.56 | 2.21 |
| Aug 20, 2024 | 2.24 | -0.05 | -2.18% | 2.29 | 2.33 | 2.19 |
| Aug 19, 2024 | 2.35 | 0.08 | 3.52% | 2.27 | 2.37 | 2.20 |
| Aug 16, 2024 | 2.33 | -0.08 | -3.32% | 2.41 | 2.44 | 2.28 |
| Aug 15, 2024 | 2.43 | 0.15 | 6.58% | 2.28 | 2.51 | 2.24 |
| Aug 14, 2024 | 2.59 | -0.08 | -3.00% | 2.67 | 2.74 | 2.46 |
| Aug 13, 2024 | 2.64 | 0.20 | 8.20% | 2.44 | 2.66 | 2.42 |
| Aug 12, 2024 | 2.43 | -0.03 | -1.22% | 2.46 | 2.67 | 2.41 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Longeveron Inc Company profile
Longeveron Inc. (LGVN) is a clinical-stage biotechnology company. Its lead drug component and cellular therapies address ageing and other life-threatening conditions. Founded in 2014, Longeveron is headquartered in Miami, US.
The biotech firm’s leading product Lomecel-B is derived from culture-expanded medicinal signalling cells (MSCs). The cells were sourced from young healthy adult donors’ - aged 18 to 45 - bone marrow to treat ageing-related diseases as they promote cell and tissue repair, organ maintenance and immune system function.
As of June 2022, the company is conducting Phase 2 clinical trials in hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease. It has received orphan drug and rare paediatric disease designations from the US Food and Drug Administration (FDA).
Longeveron is also conducting Phase 1 and 2 clinical trials for ageing frailty, metabolic syndrome and acute respiratory distress syndrome due to Covid-19 or influenza.
Longeveron’s programmes have been awarded grant funding of more than $16.2m from various organisations, including the National Institute on Ageing (NIA), National Heart Lung and Blood Institute (NHLBI), the Alzheimer’s Association and the Maryland Stem Cell Research Fund (MSCRF).
Longeveron Inc. stock started trading on the NASDAQ stock exchange in February 2021 under the ticker symbol LGVN.
You can follow live LGVN stock price movements and price history and keep up with the latest LGVN share value at Capital.com
| Industry: | Biotechnology & Medical Research (NEC) |
1951 NW 7th Ave
Ste 520
MIAMI
FLORIDA 33136
US
News
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024
FOMC PREVIEW
Markets believe the Federal reserve will continue to leave their monetary policy unchanged at the meeting next week.
14:09, 1 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com